BiotechTube
OncoNano Medicine

OncoNano Medicine

Southlake, United States· Est.
onconano.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50.7M

Overview

OncoNano Medicine is a private, clinical-stage biotech leveraging its ON-BOARD™ polymeric micelle platform to develop targeted cancer therapies. The platform exploits the universal hallmark of tumor acidity to improve drug delivery, aiming to enhance therapeutic efficacy while minimizing systemic toxicity. The company's most advanced program, ONM-501, is in Phase 1 trials, and OncoNano is actively seeking partnerships to expand the application of its delivery technology. With a seasoned leadership team and a research collaboration with Gilead, the company is positioned to advance its pipeline of novel oncology treatments.

Oncology

Technology Platform

ON-BOARD™ ultra pH-sensitive polymeric micelle platform designed to target the acidic tumor microenvironment for precise delivery of therapeutic payloads (small molecules, biologics, proteins, nucleic acids).

Funding History

3
Total raised:$50.7M
Grant$2M
Series B$23.7M
Series A$25M

Opportunities

The ON-BOARD™ platform's ability to target a universal tumor hallmark (acidity) presents a broad opportunity to improve the delivery and therapeutic index of a wide range of oncology payloads, enabling partnerships.
The growing immuno-oncology market, particularly for intratumoral agents like STING agonists, offers a significant commercial pathway for lead candidate ONM-501.

Risk Factors

The company faces high clinical risk as its lead candidate, ONM-501, is only in Phase 1 trials, and the novel delivery platform remains unproven in late-stage development.
Significant competition exists in both targeted drug delivery and the STING agonist space from larger, better-funded entities.
As a pre-revenue private company, it is dependent on raising capital to fund operations.

Competitive Landscape

OncoNano competes in the crowded fields of targeted drug delivery and STING agonist development. Competitors include other nanomedicine companies (e.g., BIND Therapeutics historically, various academic spin-offs) and numerous biopharma firms developing STING agonists (e.g., Merck, Bristol Myers Squibb, AstraZeneca). Its differentiation lies in the pH-sensitive micelle approach targeting a universal tumor feature rather than variable biomarkers.

More companies in Oncology (General) →More companies in United States →